{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:53:17Z","timestamp":1792248797606,"version":"4.4.0"},"reference-count":46,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T00:00:00Z","timestamp":1402876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:p>Constipation-predominant irritable bowel syndrome (IBS-C) is a commonly prevalent and clinically challenging disorder to treat. Until recently, most therapeutic agents had limited ability to address the complexity of symptoms inherent to the syndrome. The development of linaclotide provides a physiologically sound approach to treatment of the multiple symptoms of IBS-C. Clinical trials demonstrate the efficacy of linaclotide, and a platform to better understand the symptomatology of IBS-C. Based on recent clinical evidence, linaclotide should be considered for patients with IBS-C because it improves abdominal pain and bowel symptoms. In phase III trials, linaclotide met the US Food and Drug Administration responder endpoint with a number needed to treat (NNT) of 5.1\u20137.9, and European Medicines Agency coprimary endpoints at 12 weeks with a NNT of 4.39\u20137.69, and at 26 weeks with a NNT of 4.93\u20135.68. It is safe and effective, with diarrhea reported as the most common adverse effect, which leads to discontinuation of the medication in approximately 5% of patients.<\/jats:p>","DOI":"10.1177\/1756283x14537882","type":"journal-article","created":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T01:07:53Z","timestamp":1403053673000},"page":"193-205","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide"],"prefix":"10.1177","volume":"7","author":[{"given":"Siegfried W.B.","family":"Yu","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish S.C.","family":"Rao","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Medical College of Georgia, Georgia Regents University, BBR2540, 1120 15th Street, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,6,16]]},"reference":[{"key":"e_1_3_2_2_1","first-page":"5","article-title":"Pattern of irritable bowel syndrome and its impact on quality of life in primary health care center attendees, Suez governorate, Egypt","volume":"9","author":"Abdulmajeed A.","year":"2011","unstructured":"Abdulmajeed A., Rabab M., Sliem H., Hebatallah N. (2011) Pattern of irritable bowel syndrome and its impact on quality of life in primary health care center attendees, Suez governorate, Egypt. Pan Afr Med J 9: 5.","journal-title":"Pan Afr Med J"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.06.067"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12292"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01465.x"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90557.2008"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-200901001-00002"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2012.10.005"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2010.03.015"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.09.019"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.199430"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(13)62706-7"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00375.x"},{"key":"e_1_3_2_14_1","first-page":"S7","article-title":"Total costs of IBS: employer and managed care perspective","volume":"11","author":"Cash B.","year":"2005","unstructured":"Cash B., Sullivan S., Barghout V. (2005) Total costs of IBS: employer and managed care perspective. Am J Manag Care 11(1 Suppl.): S7-S16.","journal-title":"Am J Manag Care"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.08.017"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm.2010.16.4.389"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.254"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12151"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-200509001-00894"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37095"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01385.x"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5114-12.2013"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00542.2011"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.157594"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.041"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2013.775328"},{"key":"e_1_3_2_27_1","first-page":"A26","article-title":"Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects","volume":"130","author":"Kurtz C.","year":"2006","unstructured":"Kurtz C., Fitch D., Busby R., et al. (2006) Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Gastroenterology 130: A26.","journal-title":"Gastroenterology"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X12443093"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins2082028"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12089"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-012309-103958"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.4103\/1596-3519.57241"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.10.010"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.12.005"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12123"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.255"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.09.022"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00207.2012"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12204"},{"key":"e_1_3_2_41_1","first-page":"1910","article-title":"The epidemiology of irritable bowel syndrome in North America: a systematic review","volume":"97","author":"Saito Y.","year":"2002","unstructured":"Saito Y., Schoenfeld P., Locke G.3rd (2002) The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 97: 1910\u20131915.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00358.2003"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.05.044"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-013-1646-4"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.4.1466"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.04.032"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70197-5"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X14537882","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756283X14537882","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X14537882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:40:05Z","timestamp":1790167205000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756283X14537882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,16]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1177\/1756283X14537882"],"URL":"https:\/\/doi.org\/10.1177\/1756283x14537882","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,16]]}}}